Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lithium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 3/20 | 0.33 |
| ▸ | PRKDC | P78527 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 4/20 | 0.31 |
| ▸ | PLAU | P00749 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12466450 | 0.81 | PDPK1 (0.39) | ATRPRKDCGRM5PLAU | |
| SCHEMBL2114667 | 0.81 | ATR (0.38) | ATRPRKDC | |
| SCHEMBL3003587 | 0.80 | NPSR1 (0.47) | ATRPRKDCGRM5 | |
| SCHEMBL29804434 | 0.80 | NPSR1 (0.47) | ATRPRKDCGRM5 | |
| Lithium Ion SCHEMBL19743961 | 0.79 | ATR (0.51) | ATRPRKDCGRM5PLAU | |
| Lithium Ion SCHEMBL19743870 | 0.78 | GRM5 (0.50) | ATRPRKDCGRM5 | |
| SCHEMBL2112207 | 0.75 | ATR (0.40) | ATRGRM5 | |
| SCHEMBL14826018 | 0.75 | PLAU (0.30) | PLAU | |
| Lithium Ion SCHEMBL19743877 | 0.74 | ATR (0.37) | ATRPRKDCGRM5 | |
| SCHEMBL3374259 | 0.73 | CDK5 (0.43) | ATRPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10759785-B2 | Compounds | Enterprise Therapeutics Limited (GB) | 2020-09-01 | — | — | US | disclosed |
| EP-3472154-B1 | COMPOUNDS | ENTERPRISE THERAPEUTICS LTD (GB) | 2020-08-12 | — | — | EP | disclosed |
| US-20190233402-A1 | COMPOUNDS | Enterprise Therapeutics Limited (GB) | 2019-08-01 | — | — | US | disclosed |
| EP-3472154-A1 | COMPOUNDS | Enterprise Therapeutics Limited (GB) | 2019-04-24 | — | — | EP | disclosed |
| WO-2017221008-A1 | COMPOUNDS | Enterprise Therapeutics Limited (GB) | 2017-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190233402-A1 | COMPOUNDS | CFTR, NHERF1, SCNN1A | ATR 3410/4885PRKDC 4869/4885GRM5 1713/4885 |
| US-10759785-B2 | Compounds | CFTR, NHERF1, SCNN1A | ATR 3410/4885PRKDC 4869/4885GRM5 1713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.